MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Medtronic plc
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026
$92.77−1.98 (-2.09%)
Close on Oct 19, 2026
- Market cap
- $119.22B
- P/E (TTM)
- 22.8
- Dividend yield
- 3.06%
Medtronic plc revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable segment net sales | $33.08B | $30.73B | $29.65B | $30.73B | $30.96B | – | – | – | – | – | 91.0% | +7.6% |
| Cardiovascular | $13.98B | $12.48B | $11.83B | $11.52B | $11.37B | $10.77B | $10.47B | – | – | – | 38.4% | +12.0% |
| Neuroscience | $10.29B | $9.85B | $9.41B | $8.96B | $8.78B | – | – | – | – | – | 28.3% | +4.5% |
| Medical Surgical | $8.82B | $8.41B | $8.42B | $7.99B | $8.47B | – | – | – | – | – | 24.2% | +4.9% |
| Other Operating Segments, Including Diabetes | $3.25B | $2.89B | $2.71B | – | – | – | – | – | – | – | 8.9% | +12.3% |
| Diabetes | $3.11B | $2.76B | $2.49B | $2.26B | $2.34B | – | $2.37B | $2.39B | $2.14B | $1.93B | 8.6% | +13.0% |
| Other operating segment, misc | $135.00M | $137.00M | $221.00M | – | – | – | – | – | – | – | 0.4% | -1.5% |
| Restorative Therapies Group | – | – | – | – | – | – | $7.73B | $8.18B | $7.74B | $7.37B | – | – |
| Cardiac & Vascular Group | – | – | – | – | – | – | $10.47B | $11.51B | $11.35B | $10.50B | – | – |
| Minimally Invasive Therapies Group | – | – | – | – | – | – | $8.35B | $8.48B | $8.72B | $9.92B | – | – |
| Medical Surgical | – | – | – | $8.43B | $9.14B | $8.74B | $8.35B | $8.48B | – | – | – | – |
| Diabetes | – | – | – | $2.26B | $2.34B | $2.41B | $2.37B | $2.39B | – | – | – | – |
| Cardiovascular | – | – | – | – | – | $10.77B | $10.47B | $11.51B | – | – | – | – |
| Neuroscience | – | – | – | $8.96B | $8.78B | $8.20B | $7.73B | $8.18B | – | – | – | – |
| Other Operating Segments | – | $137.00M | $221.00M | $495.00M | $727.00M | – | – | – | – | – | – | – |
| Other Segment | – | $137.00M | $221.00M | $495.00M | – | – | – | – | – | – | – | – |
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $3.67B | $3.34B | $3.08B | $4.52B | $4.60B | $3.85B | $3.72B | – | – | – | +9.8% |
| Neuroscience | $3.06B | $3.03B | $2.82B | $3.71B | $3.86B | – | – | – | – | – | +1.0% |
| Medical Surgical | $2.13B | $2.07B | $2.19B | $3.05B | $3.70B | – | – | – | – | – | +2.8% |
| Other Operating Segments, Including Diabetes | $106.00M | $214.00M | $96.00M | – | – | – | – | – | – | – | -50.5% |
| Diabetes | – | $491.00M | $394.00M | $383.00M | $588.00M | – | $546.00M | $739.00M | $634.00M | – | – |
| Restorative Therapies Group | – | – | – | – | – | – | $2.92B | $3.32B | $3.06B | – | – |
| Cardiac & Vascular Group | – | – | – | – | – | – | $3.72B | $4.53B | $4.46B | – | – |
| Minimally Invasive Therapies Group | – | – | – | – | – | – | $3.04B | $3.26B | $3.35B | – | – |
| Medical Surgical | – | – | – | $2.86B | $3.57B | $3.02B | $3.04B | $3.26B | – | – | – |
| Diabetes | – | – | – | $378.00M | $583.00M | $598.00M | $546.00M | $739.00M | – | – | – |
| Cardiovascular | – | – | – | – | – | $3.85B | $3.72B | $4.53B | – | – | – |
| Neuroscience | – | – | – | $3.62B | $3.77B | $3.16B | $2.92B | $3.32B | – | – | – |
| Other Operating Segments | – | – | $10.00M | -$89.00M | -$31.00M | – | – | – | – | – | – |
| Other Segment | – | $49.00M | $10.00M | -$89.00M | – | – | – | – | – | – | – |
By product or service
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total other countries, excluding Ireland | $36.22B | $33.42B | $32.25B | $31.13B | $31.59B | $30.02B | $28.83B | $30.47B | $29.87B | $29.64B | 99.6% | +8.4% |
| International | $18.26B | $16.37B | $15.80B | – | – | – | – | – | – | – | 50.2% | +11.6% |
| Rest of world | $18.12B | $16.25B | $15.69B | $14.76B | $15.45B | $14.49B | $13.91B | $14.27B | $13.99B | $12.98B | 49.8% | +11.5% |
| United States | $18.10B | $17.17B | $16.56B | $16.37B | $16.14B | $15.53B | $14.92B | $16.19B | $15.88B | $16.66B | 49.8% | +5.4% |
| Ireland | $143.00M | $116.00M | $113.00M | $98.00M | $101.00M | $100.00M | $85.00M | $91.00M | $85.00M | $69.00M | 0.4% | +23.3% |
| Americas | – | – | – | – | – | – | – | – | – | $17.94B | – | – |
| Asia-Pacific | – | – | – | – | – | – | – | – | – | $3.44B | – | – |
| EMEA | – | – | – | – | – | – | – | – | – | $6.74B | – | – |
| China | – | – | – | – | – | – | – | – | – | $1.59B | – | – |
| Non-U.S. Developed Markets | – | – | $9.98B | $9.41B | $10.13B | $9.82B | $9.29B | $9.63B | $9.63B | $9.09B | – | – |
| Emerging Markets | – | – | $5.82B | $5.45B | $5.43B | $4.78B | $4.71B | $4.73B | $4.45B | $3.96B | – | – |
| International | – | $16.37B | $15.80B | $14.85B | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Medtronic's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.